Market Signal Briefing

Allegiant said Sunday it is acquiring fellow budget carrier Sun Country in a $1.5 billion cash deal.

The plan for a combination comes as budget airlines in the U.S. have faced a surge in costs following the pandemic and the increase in domestic capacity.

The transaction has an implied value of  $18.89 for each Sun Country share. That carrier's shareholders will receive 0.1557 shares of Allegiant common stock and $4.10 in cash for each Sun Country share owned, Allegiant said Sunday.

The deal is a premium of almost 20% over Sun Country's closing stock price on Friday, the airline said.

The deal will test the Trump administration's appetite for an airline merger.

The Biden administration challenged JetBlue Airways' acquisition of Spirit Airlines, which is now in its second bankruptcy and fighting for survival. A federal judge sided with the Biden Justice Department and blocked the JetBlue-Spirit deal.

Read more CNBC airline newsBoeing's deliveries are highest in 7 years. It's about to pick up the paceWhy airline class wars will intensify in 2026American Airlines no longer lets basic economy flyers earn milesArchitect of Delta's premium strategy to retire in FebruaryFrontier Airlines replaces longtime CEO Barry Biffle with carrier's presidentThe Biden administration, however, did clear Alaska Air's nearly $2 billion acquisition of Hawaiian Airlines in 2024.

This is breaking news. Please refresh for updates.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.

Full Year 2025 Select, Preliminary, Unaudited Financial Results

Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry) Diagnostics revenue of ~$955 million, representing ~111% growth year-over-year, driven by Oncology volume growth of ~26% and Hereditary volume growth of ~29% Data and applications revenue of ~$316 million, representing ~31% growth year-over-year, driven by ~38% growth in Insights (Data Licensing) Fourth Quarter 2025 Select, Preliminary, Unaudited Financial Results

Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth of ~29% and Hereditary volume growth of ~23% Data and applications revenue of ~$100 million, representing ~25% year-over-year growth, with Insights growing ~68%, excluding the impact of the AstraZeneca warrant in Q4 of 2024. “2025 was an exceptional year for Tempus with the strength of both of our product lines exceeding our initial expectations for the year,” said Eric Lefkofsky, Founder and CEO of Tempus. “Within Diagnostics, year-over-year volume growth of our genomics (oncology) offering accelerated for the third consecutive quarter hitting the highest unit growth rate we have seen in years. Our Data and Application business is performing even better with record revenue of ~$100 million in the fourth quarter, achieving full-year growth of ~31%, with our data licensing business growing ~38%. We enter 2026 in an exceptionally strong position with both of our main businesses accelerating in growth and delivering the financial leverage inherent in our platform. With AI as a catalyst across all of our products, we couldn’t be more excited for 2026.”

This announcement comes ahead of the Company’s presentation today at the 44th Annual J.P. Morgan Healthcare Conference. A live webcast of the presentation and our updated investor deck can be found on Tempus’ investor relations website at investors.tempus.com.

Tempus has not completed preparation of its financial statements for the fourth quarter or full year 2025. The estimates disclosed in this release for the fourth quarter and year ended December 31, 2025, are preliminary, and unaudited and inherently uncertain, and therefore subject to change as Tempus completes preparation of its financial results for these periods. Tempus is in the process of completing its customary year-end close and review procedures for the quarter and year ended December 31, 2025, and there can be no assurance that final results for these periods will not differ from these estimates, and any such difference may be material. During the preparation of Tempus’ consolidated financial statements for the year ended December 31, 2025, Tempus or its independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.

Tempus plans to report its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ preliminary, unaudited financial results for fourth quarter and full year 2025 and Tempus’ expected financial results for full year 2026. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; completed and future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”), as supplemented by Tempus’ Quarterly Report on Form 10-Q for the period ended September 30, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

More News From Tempus AI, Inc.

− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) –

− Company Provides 2026 Combined Net Product Revenue Guidance of $4,900 Million to $5,300 Million, Driven Primarily by Total TTR Net Product Revenue Guidance of $4,400 Million to $4,700 Million –

– 2026 Pipeline Goals Focused on Continued Advancement of Numerous Multi-Billion-Dollar Opportunities –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO.

New Five-Year Strategy: Alnylam 2030

Alnylam 2030 continues the Company’s 15-year heritage of establishing and delivering on ambitious five-year goals, the most recent of which was Alnylam P5x25. Over that time period, Alnylam has either met or exceeded all of its prior five-year goals.

Alnylam 2030 is focused on continuing to successfully scale the Company’s operations. Specifically, the Company intends to achieve the following by the end of 2030:

Achieve Global TTR Leadership: Build a Durable TTR Franchise Lead TTR market in revenue by 2030 and cumulatively across five-year period Launch best-in-class, next-gen silencer, nucresiran, in polyneuropathy by 2028 and cardiomyopathy by 2030 Grow Through Sustainable Innovation: Deliver Therapies that Prevent, Halt, or Reverse Disease Deliver 2+ new transformative medicines beyond TTR with blockbuster potential Expand to 10 tissue types and >40 clinical programs Invest ~30% of revenues in non-GAAP R&D, including select external innovation Scale with Discipline & Agility: Drive Sustained, Profitable Growth Achieve 25%+ total revenue CAGR through year-end 2030 Deliver ~30% non-GAAP operating margin “The past five years have been transformational, as we delivered on our ambitious goals to expand the reach of our commercial product portfolio, grow our pipeline of transformative RNAi therapeutics, and achieve strong financial results leading to sustainable profitability,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “The success we have delivered with the early launch momentum of AMVUTTRA in ATTR-CM has laid the foundation for our first flagship commercial franchise. Our focus for the next five-year period is clear: continue to establish durable leadership in TTR; harness topline growth to invest in a high-yielding pipeline with blockbuster opportunities; and continue to operate with financial discipline and agility to enable the Company to scale efficiently. As the pioneer in RNAi therapeutics that has delivered six approved products, Alnylam 2030 provides the strategic direction to catalyze our growth during the next stage of our evolution.”

Preliminary Fourth Quarter and Full Year 2025 Commercial and Financial Performance*

Total TTR: AMVUTTRA® (vutrisiran) & ONPATTRO® (patisiran)

Preliminary* global net product revenues for AMVUTTRA and ONPATTRO for the fourth quarter were approximately $827 million and $32 million, respectively, together representing 151% total TTR growth compared to Q4 2024, and for the full year 2025 were approximately $2,314 million and $173 million, respectively, together representing 103% total TTR growth compared to full year 2024. Total Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran)

Preliminary* global net product revenues for GIVLAARI and OXLUMO for the fourth quarter were approximately $87 million and $50 million, respectively, together representing 26% total Rare growth compared to Q4 2024, and for the full year 2025 were approximately $308 million and $191 million, respectively, together representing 18% total Rare growth compared to full year 2024. 2026 Combined Net Product Revenue Guidance

Alnylam announced today full year 2026 combined net product revenue guidance for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO of $4,900 million to $5,300 million, representing 71% growth compared to 2025* at the mid-point of the guidance range. On a franchise level, the guidance is as follows:

Total TTR (AMVUTTRA & ONPATTRO): $4,400 million to $4,700 million, representing 83% growth compared to 2025* at the mid-point of the guidance range. Total Rare (GIVLAARI & OXLUMO): $500 million to $600 million, representing 10% growth compared to 2025* at the mid-point of the guidance range. The Company plans to provide additional guidance for collaboration and royalty revenue and operating expenses when fourth quarter and full year 2025 earnings are released.

2026 Pipeline Goals

Nucresiran – an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis. Alnylam expects to:

Advance the TRITON-CM Phase 3 trial in ATTR-CM and the TRITON-PN Phase 3 trial in hATTR-PN. Zilebesiran – an investigational RNAi therapeutic in development for the treatment of hypertension, in collaboration with Roche. Alnylam expects to:

Advance the ZENITH Phase 3 cardiovascular outcomes trial. Mivelsiran – an investigational RNAi therapeutic in development for the treatment of cerebral amyloid angiopathy (CAA) and Alzheimer’s disease. Alnylam expects to:

Complete enrollment of the cAPPricorn-1 Phase 2 trial in cerebral amyloid angiopathy in H1. Initiate a Phase 2 trial in Alzheimer’s disease in H1. ALN-6400 – an investigational RNAi therapeutic in development for the treatment of bleeding disorders. Alnylam expects to:

Report Phase 1 data in healthy volunteers in H2. Report clinical proof of concept in hereditary hemorrhagic telangiectasia in H2. Initiate a Phase 2 trial in a second bleeding disorder in H1. ALN-4324 – an investigational RNAi therapeutic in development for the treatment of type 2 diabetes mellitus. Alnylam expects to:

Initiate a Phase 2 trial in H1. ALN-HTT02 – an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, in collaboration with Regeneron. Alnylam expects to:

Report Phase 1 data in H2. ALN-2232 – an investigational RNAi therapeutic in development for the treatment of obesity & weight management. Alnylam expects to:

Report Phase 1 data in H2. In addition, the Company plans to file Investigational New Drug (IND) applications for three to four new Alnylam-led programs by the end of 2026.

Alnylam management will discuss its preliminary 2025 net product revenues, as well as 2026 goals and guidance during a webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California tomorrow, Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET).

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Alnylam Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding: Alnylam’s potential achievement of the goals in its “Alnylam 2030” strategy and its ability to drive the next era of growth and patient impact; Alnylam’s ability to achieve global TTR leadership, drive long-term growth through sustainable innovation, and deliver exceptional financial results with discipline and agility; the size of the opportunities of any of the product candidates in Alnylam’s pipeline; the potential for AMVUTTRA in ATTR-CM to be Alnylam’s flagship commercial franchise; the potential for Alnylam to advance its research and development programs, including its goals and expectations regarding the clinical development of nucresiran, zilebesiran, mivelsiran, ALN-6400, ALN-4324, ALN-HTT02, and ALN-2232, including the timeline of the initiation, completion of enrollment, and reporting of data and/or proof of concept from, any clinical trials; the number of IND applications Alnylam plans to file for Alnylam-led programs by the end of 2026; and Alnylam’s projected commercial and financial performance, including the expected range of global net product revenues for 2026 should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to Alnylam’s ability to successfully execute on its “Alnylam 2030” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates, including nucresiran, zilebesiran, mivelsiran, ALN-6400, ALN-4324, ALN-HTT02, and ALN-2232; the possibility of unfavorable new clinical data and further analyses of existing clinical data; interim and preliminary data; the possibility that clinical data are subject to differing interpretations and assessments by regulatory agencies; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam’s approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam’s product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation; the potential risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing Alnylam’s views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Use of Non-GAAP Financial Measures

This press release contains references to forward-looking financial measures of non-GAAP R&D and non-GAAP operating margin that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). We do not provide a reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP on a forward-looking basis because such reconciliation is not accessible with reasonable effort, due to the uncertainty and inherent difficulty of predicting the occurrence and the financial impact of adjustments, such as stock-based compensation expense; such adjustments could be material. We use these non-GAAP measures as an indicator of financial performance for the purpose of internal evaluation of progress toward financial objectives. We also believe that these non-GAAP measures provide investors with useful information with respect to our operational goals. A non-GAAP financial measure is not, and should not be viewed as, a substitute for financial measures required by GAAP, has no standardized meaning prescribed by GAAP, and may not be comparable to the calculation of the measure by other companies.

* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2026.

More News From Alnylam Pharmaceuticals, Inc.

– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –

– $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through December 31, 2025 –

– Company poised for breakthrough progress in 2026 with deep pipeline of potentially transformative therapies –

SAN DIEGO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today highlighted recent accomplishments, reported preliminary KOMZIFTI™ (ziftomenib) net product revenue and outlined anticipated 2026 milestones.

“Following the landmark FDA approval of KOMZIFTI on November 13, 2025, we are executing a robust commercial launch to drive rapid adoption and market share growth,” said Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology. “With KOMZIFTI's compelling efficacy, favorable safety profile and ease of use, we believe that we are strongly positioned for success and encouraged by the first few weeks of our commercial launch. Our comprehensive development strategy advances ziftomenib into combinations and earlier lines of therapy, including newly diagnosed patients with NPM1 mutations, KMT2A rearrangements, and FLT3 mutations, supported by our expanding pipeline programs and solid cash position. We are excited to deliver meaningful impact for patients throughout 2026 and beyond.”

Preliminary Fourth Quarter Financial Highlights

$2.1 million of KOMZIFTI net product revenue in the five-week period of initial commercial availability ended December 31, 2025.Milestone payments of $195 million under collaboration agreement with Kyowa Kirin in the fourth quarter of 2025.Collaboration revenue (non-cash item) for the fourth quarter of 2025 estimated between $15 to $17 million. 
$667.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025. Recent Program Highlights

In November 2025, KOMZIFTI was granted full approval by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated (NPM1-m) AML, a devastating blood cancer with limited treatment options.In November 2025, KOMZIFTI was added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a Category 2A recommended treatment option for adults with R/R NPM1-m AML.In December 2025, two oral presentations at the 67th Annual Meeting of the American Society of Hematology (ASH 2025) reported a favorable safety profile and encouraging antileukemic activity for ziftomenib in combination with venetoclax and azacitidine (ven/aza) in patients with AML harboring NPM1 mutations or KMT2A rearrangements (KMT2A-r). These data came from the ongoing Phase 1a/1b KOMET-007 trial (NCT05735184), which includes patients with newly diagnosed NPM1-m AML as well as patients with R/R NPM1-m or KMT2A-r AML.In September 2025, the first patient was dosed in the Phase 3 KOMET-017 (NCT07007312) trial evaluating ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-m or KMT2A-r AML.In October 2025, compelling preliminary data from Kura’s first- and next-generation farnesyl transferase inhibitor (FTI) programs – tipifarnib and darlifarnib – were presented at the 2025 European Society for Medical Oncology (ESMO) Congress.   Expected 2026 Key Milestones

KOMZIFTI Commercial

Accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML.Drive quarter-over-quarter growth in net product revenue. Ziftomenib Development

Present updated KOMET-007 data evaluating combination with 7+3 in newly diagnosed NPM1-m or KMT2A-r AML in the first half of 2026.Publish ven/aza combination data in R/R NPM1-m AML in the first half of 2026.Present preliminary data from KOMET-008 cohort evaluating combination with gilteritinib in R/R NPM1-m/FLT3-m AML in the second half of 2026. Advance enrollment of KOMET-017 Phase 3 trials for newly diagnosed AML, including combinations with intensive and non-intensive chemotherapy, in 2026.Advance enrollment of KOMET-007 cohort evaluating combination with 7+3 and quizartinib in newly diagnosed NPM1-m/FLT3-m AML (quad) in 2026.Expand ziftomenib to non-AML indications in 2026, including ongoing Phase 1a dose escalation trial evaluating combination with imatinib in gastrointestinal stromal tumors. Darlifarnib Development

Initiate expansion cohorts of darlifarnib and cabozantinib in advanced renal cell carcinoma (RCC) (Phase 1b) in the first half of 2026.Present preliminary data from darlifarnib and adagrasib in KRASG12C-mutated solid tumors (non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma) in the first half of 2026.Present updated dose-escalation data from darlifarnib and cabozantinib in advanced RCC (Phase 1a) in the second half of 2026.Explore opportunities to evaluate additional indications and combination agents in 2026. Pipeline

Publish preclinical menin inhibitor data on diabetes in the second half of 2026.                                                                                   Advance KO-7246, next generation menin inhibitor, in IND-enabling studies for diabetes and cardiometabolic diseases in 2026.Advance preclinical development of a next-generation menin inhibitor development candidate for use in combination therapy for solid tumors in 2026. 2026 Financial Guidance

Kura anticipates non-cash collaboration revenue recognition of $45 million to $55 million in 2026.$667.3 million in cash, cash equivalents and short-term investments as of December 31, 2025, together with anticipated short-term collaboration payments and product revenue, expected to support ziftomenib AML program through topline results in front-line Phase 3 trial in newly-diagnosed AML.
About KOMZIFTI™ (ziftomenib)
KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.

Ziftomenib is in development for the front-line treatment of AML harboring NPM1 mutations, KMT2A translocations and FLT3 mutations, with the potential to be combined with approved therapies and benefit a broad spectrum of patients earlier in their disease course.

IMPORTANT SAFETY INFORMATION FOR KOMZIFTI FROM THE U.S. PRESCRIBING INFORMATION

Boxed WARNING: DIFFERENTIATION SYNDROME

Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI, and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome

KOMZIFTI can cause fatal or life-threatening differentiation syndrome (DS). DS is associated with rapid proliferation and differentiation of myeloid cells. Symptoms of DS, including those seen in patients treated with KOMZIFTI, may include fever, hypoxia, joint pain, hypotension, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, acute kidney injury, and rashes.

In the clinical trial, DS occurred in 29 (26%) of 112 patients with R/R AML with an NPM1 mutation who were treated with KOMZIFTI at the recommended dosage. DS was Grade 3 in 13% and fatal in two patients. In broader evaluation of all patients with any genetic form of AML treated with KOMZIFTI monotherapy in clinical trials, DS occurred in 25% of patients. Four fatal cases of DS occurred out of 39 patients with KMT2A-rearranged AML treated with KOMZIFTI. KOMZIFTI is not approved for use in patients with KMT2A-rearranged AML.

In the 112 patients with an NPM1 mutation, DS was observed with and without concomitant hyperleukocytosis, in as early as 3 days and up to 46 days after KOMZIFTI initiation. The median time to onset was 15 days. Two patients experienced more than one DS event. Treatment was interrupted and resumed in 15 (13%) patients, while it was permanently discontinued in 2 (2%) patients.

Prior to starting treatment with KOMZIFTI, reduce the WBC counts to less than 25 x 10⁹/L. If DS is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring. Resume treatment with KOMZIFTI at the same dose level when signs and symptoms improve and are Grade 2 or lower. Taper corticosteroids over a minimum of 3 days after adequate control or resolution of symptoms. Symptoms of DS may recur with premature discontinuation of corticosteroid treatment.

QTc Interval Prolongation

KOMZIFTI can cause QTc interval prolongation. In the clinical trial, QTc interval prolongation was reported as an adverse reaction in 12% of 112 patients treated with KOMZIFTI at the recommended dosage for R/R AML with an NPM1 mutation. QTc interval prolongation was Grade 3 in 8% of patients. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 9% of patients, and the increase from baseline QTcF was greater than 60 msec in 12% of patients. KOMZIFTI dose reduction was required for 1% of patients due to QTc interval prolongation. QTc prolongation occurred in 14% of the 42 patients less than 65 years of age and in 10% of the 70 patients 65 years of age or older.

Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with KOMZIFTI. Perform an ECG prior to initiation of treatment with KOMZIFTI, and do not initiate KOMZIFTI in patients with QTcF > 480 msec. Perform an ECG at least once weekly for the first four weeks on treatment, and at least monthly thereafter. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms (Grade 3). In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of KOMZIFTI with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsades de Pointes, other serious arrhythmias, and sudden death.

Embryo-Fetal Toxicity

Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 3 months after the last dose.

ADVERSE REACTIONS

Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).

Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. Adverse reactions that required dose interruption in ≥ 2% of patients included infection without an identified pathogen (15%), differentiation syndrome (13%), febrile neutropenia (5%), pyrexia (4%), electrocardiogram QT prolonged (4%), leukocytosis (4%), bacterial infection (3%), cardiac failure (2%), cholecystitis (2%), diarrhea (2%), pruritus (2%), and thrombosis (2%). Dose reduction of KOMZIFTI due to an adverse reaction occurred in 4% of patients. Permanent discontinuation of KOMZIFTI due to an adverse reaction occurred in 21% of patients. Adverse reactions that required permanent discontinuation of KOMZIFTI in ≥ 2% of patients were infection without an identified pathogen (8%), bacterial infection (4%), cardiac arrest (2%), and differentiation syndrome (2%).

Most common (≥ 20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased (53%), infection without an identified pathogen (52%), potassium decreased (52%), albumin decreased (51%), alanine aminotransferase increased (50%), sodium decreased (49%), creatinine increased (45%), alkaline phosphatase increased (41%), hemorrhage (38%), diarrhea (36%), nausea (35%), fatigue (34%), edema (30%), bacterial infection (28%), musculoskeletal pain (28%), bilirubin increased (27%), potassium increased (26%), differentiation syndrome (26%), pruritus (23%), febrile neutropenia (22%), and transaminases increased (21%).

DRUG INTERACTIONS

Drug interactions may occur when KOMZIFTI is concomitantly used with:

Strong or Moderate CYP3A4 Inhibitors: Monitor patients more frequently for KOMZIFTI-associated adverse reactions.Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of KOMZIFTI.Gastric Acid Reducing Agents: Avoid concomitant use of KOMZIFTI with proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), or locally acting antacids. If concomitant use with H2RAs or locally acting antacids cannot be avoided, modify KOMZIFTI administration time. Take KOMZIFTI 2 hours before or 10 hours after administration of an H2 receptor antagonist.Take KOMZIFTI 2 hours before or 2 hours after administration of a locally acting antacid. Drugs that Prolong the QTc Interval: Avoid concomitant use of KOMZIFTI. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms. USE IN SPECIFIC POPULATIONS

Pregnancy: Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to starting KOMZIFTI.

Lactation: Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with KOMZIFTI and for 2 weeks after the last dose.

Infertility: Based on findings in animals, KOMZIFTI may impair fertility in females and males of reproductive potential.

Please see full Prescribing Information, including Boxed WARNING.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

The preliminary financial metrics discussed above and in this news release are subject to the completion of financial closing procedures and other developments that may arise between now and the time the financial results for the fourth quarter of 2025 are finalized, as well as the completion of the audit of the 2025 financial statements. Therefore, actual results may differ materially from these estimates. In addition, the above estimates do not present all information necessary for an understanding of Kura’s financial condition as of December 31, 2025.

Kura Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura’s future operations, financial results and financial condition; Kura’s performance in 2026; the strength of Kura’s cash position; Kura’s anticipated cash runway; Kura’s research, preclinical and clinical development activities; plans and projected timelines for ziftomenib, darlifarnib and preclinical assets; expectations regarding the therapeutic potential of KOMZIFTI and Kura’s product candidates; expectations regarding the commercial potential of KOMZIFTI; and anticipated 2026 non-cash collaboration revenue recognition. Factors that may cause actual results to differ materially include risks associated with market competition, market acceptance and commercialization of KOMZIFTI; risks associated with the conduct of preclinical studies and clinical trials; risks that Kura’s actual future financial and operating results may differ from its expectations or goals; the risk that Kura’s product candidates may not receive regulatory approval; the potential for KOMZIFTI or Kura’s product candidates to have unexpected adverse side effects; the risk that Kura may not be able to obtain additional financing; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
[email protected]

Nebius expects jaw-dropping growth in 2026.

CoreWeave (CRWV +3.61%) is a well-known cloud infrastructure company that many artificial intelligence (AI) hyperscalers are farming out computing loads to these days. Not every AI hyperscaler has the capacity they need to process all the workloads they want to run, and having some infrastructure that is owned by a different entity is also a smart move because it eliminates a single point of failure.

However, CoreWeave isn't the only company in this space. There are several other competitors, but my favorite is Nebius (NBIS +0.65%), which operates in a similar field as CoreWeave and offers graphics processing units (GPUs) in a full-stack platform to give its clients everything they need to run AI workloads on its servers.

Nebius could be primed for monster gains in 2026, but is it a better bet than CoreWeave? Let's find out.

Image source: Getty Images.

Nebius has huge expansion plans in 2026 Nebius was formerly a part of Yandex, the Russian equivalent of Alphabet's Google. After sanctions came down from Russia's war with Ukraine, Yandex decided to split its Russian and non-Russian assets, and Nebius was spun out. Nebius has been highly successful in its AI-focused cloud computing business, and it looks like it's slated to boom heading into 2026.

In Q3, Nebius grew its revenue by 355% year over year. A stat like that is enough to get any growth investor excited, but it gets better. In Q3, it had an annual run rate of $551 million. By the end of 2026, that figure is expected to be between $7 billion and $9 billion!

That's huge growth and shows how in-demand AI computing power is. It's so much growth that Nebius had to increase its contract power from 1 gigawatt to 2.5 gigawatts. If Nebius delivers that kind of growth, the upside for its stock could be massive.

Nebius stock may look expensive now, but it isn't At 64 times sales, Nebius certainly looks expensive, but that's the wrong metric to use. The correct one to use is the forward sales metric, as it factors in the monster growth Nebius expects.

NBIS PS Ratio data by YCharts

Now, there's certainly risk here, as there's no guarantee that Nebius delivers on its projections. Still, by the end of the year, Nebius will be much smaller than CoreWeave. CoreWeave is also experiencing massive growth and will be much larger than Nebius at the end of 2026. I'd expect Nebius to follow a similar growth trajectory as CoreWeave as long as AI spending stays up, which could be huge news for the stock.

NBIS Revenue Estimates for Next Fiscal Year data by YCharts

The biggest question surrounding both of these stocks is when they will make money. Currently, they're in the market-capturing phase of their development, where they are expanding as quickly as possible without worrying about profitability. This works well for some time, but eventually each will need to turn a profit. That likely won't happen for a few years, as there is unreal demand for computing capacity currently.

A fully mature cloud computing company like Amazon Web Services posts operating margins of 35%. If each of these companies could achieve that level of profitability, they would be considered highly successful businesses. But what kind of returns can we expect in 2026 if we know that neither of them will turn a profit?

Today's Change

(

0.65

%) $

0.63

Current Price

$

97.93

Ideal operating margins like AWS posts are akin to subscription software companies, which usually trade around 10 to 20 times sales. That leaves plenty of room for the stock to double, but CoreWeave is also in the same boat. It really depends on the market's appetite for growth-at-all-costs companies like CoreWeave and Nebius.

If the market is willing to take on risk, these two could soar. If they aren't, then these two may post massive growth in 2026, and the market will demand profitability. We'll see where the market heads, but I still wouldn't be surprised to see Nebius double this year.

Focused on therapies for endocrine and oncologic conditions, this biotech reported significant insider selling in its latest SEC filing.

On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (CORT +2.65%), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately $703,656, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)20,000Transaction value$703,656Post-transaction shares (direct)1,235Post-transaction value (direct ownership)$44,188.30Key questionsWhat is the derivative context of this transaction?
This event involved the exercise of 20,000 stock options immediately followed by sale of the resulting common shares on the open market, with no indirect vehicles or gifting components.How did this transaction affect William Guyer's direct ownership?
Direct common stock holdings declined from 21,235 shares to 1,235 shares, a reduction of 94.18% of his direct equity stake; however, he also reported holding stock options underlying 250,000 shares after the transaction.What is the remaining equity exposure after this transaction?
After this sale, Guyer retains 1,235 directly held shares valued at approximately $44,188.Company overviewMetricValuePrice (as of market close Tuesday)$35.18Market capitalization$3.94 billionRevenue (TTM)$741.17 millionNet income (TTM)$106.11 million* 1-year performance is calculated using Tuesday as the reference date.

Company snapshotCorcept Therapeutics generates revenue primarily from Korlym, an FDA-approved therapy for Cushing's syndrome, and is advancing a pipeline of selective cortisol modulators targeting metabolic, oncologic, and neuropsychiatric disorders.The company operates a drug discovery, development, and commercialization model, monetizing proprietary therapies through direct sales and ongoing clinical development of new indications.Its primary customers include healthcare providers and specialists treating patients with endocrine and oncology disorders in the United States.Corcept Therapeutics is a mid-cap biotechnology company focused on the development and commercialization of therapies for severe endocrine and oncologic conditions. The company leverages expertise in cortisol modulation to address unmet medical needs, supported by a growing portfolio of proprietary drug candidates. Corcept's established market presence in Cushing's syndrome and its advancing clinical pipeline provide a foundation for continued growth and competitive differentiation in specialized therapeutic markets.

What this transaction means for investorsCorcept’s stock had been one of the market’s quiet winners for most of the past year before a sharp collapse on Dec. 31, following the FDA’s complete response letter for relacorilant; however, the Form 4 shows the transaction stemmed from an option exercise, not a reduction in long-term exposure. While Guyer’s direct common stock position fell sharply, his remaining equity exposure is overwhelmingly derivative, with options representing far more upside sensitivity than the small number of shares retained outright. That structure suggests portfolio management rather than a shift in outlook.

Fundamentally, Corcept entered the regulatory setback from a position of strength. Third-quarter revenue rose to $207.6 million, up from $182.5 million a year earlier, driven by continued growth in Korlym prescriptions. Management reaffirmed full-year revenue guidance of $800 million to $850 million and ended the quarter with $524 million in cash and investments, providing balance sheet flexibility even amid clinical uncertainty.

Ultimately, options-related selling amid a regulatory shock should not be conflated with a weakening core business. The real signal remains clinical execution and the path forward for relacorilant, not a single administrative liquidity event.

GlossaryForm 4: A required SEC filing disclosing insider trades of company securities by officers, directors, or major shareholders.
Exercised (stock options): The act of converting stock options into actual company shares, usually by paying a set price.
Open-market transaction: Buying or selling securities on a public exchange rather than through private or internal company arrangements.
Direct holdings: Shares owned personally by an individual, not through trusts, funds, or other entities.
Option shares: Shares obtained by exercising stock options, typically granted as part of employee compensation.
Indirect entities: Organizations or accounts, such as trusts or funds, used to hold shares on behalf of an individual.
Gifting components: The transfer of shares to another party as a gift, rather than through sale or purchase.
Equity exposure: The value or proportion of a person’s investment in a company’s shares.
Outstanding shares: Total shares of a company that are currently owned by all shareholders, including restricted shares.
Clinical pipeline: A company’s portfolio of drug candidates in various stages of research and development.
Cortisol modulator: A drug designed to alter the body’s response to the hormone cortisol, often for therapeutic purposes.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Corcept Therapeutics. The Motley Fool has a disclosure policy.

These stocks are poised for substantial growth.

The "Magnificent Seven" are among the most profitable and cash-rich businesses on the planet. These companies are driving the growth in artificial intelligence (AI) -- a market that could lead to trillions in economic value in the coming years.

Amazon (AMZN +0.50%) and Alphabet (GOOG +1.05%) (GOOGL +1.02%) are two members of this elite group of tech titans that could see substantial growth where it counts. Here's why these stocks can power your portfolio through the end of the decade.

Image source: Getty Images.

1. Amazon Amazon has created tremendous wealth for investors over the last 20 years. It is a rock-solid business that benefits from several growing revenue streams, including advertising, merchant services, and subscriptions with Prime. It also just happens to be the leader in the $390 billion cloud computing market.

All these businesses are growing, driving Amazon's total revenue up 13% year over year in the third quarter, reaching $180 billion in quarterly revenue. However, free cash flow has fallen over the last year as Amazon increased capital spending to support growth in the cloud market and other initiatives. After surging the past few years, the stock stalled in 2025, underperforming the market.

Today's Change

(

0.50

%) $

1.23

Current Price

$

247.52

Amazon spent nearly $120 billion in capital expenditures on a trailing-12-month basis through the third quarter, representing a year-over-year increase of 72%. Wall Street is concerned that this spending will pressure the company's margins, but Amazon has a long history of seeing higher profitability following these investment cycles.

This spending is primarily supporting cloud computing demand, but it also includes investments in improving fulfillment efficiency in the e-commerce business. Amazon has deployed over 1 million robots across its fulfillment network, which is significantly reducing operating costs. This could contribute to explosive growth in Amazon's free cash flow over the next five years.

Amazon stock has delivered a 700% return over the last decade, supported by a significant increase in free cash flow from $7 billion in 2015 to an expected $20 billion in 2025. By 2029, analysts expect Amazon's free cash flow to exceed $142 billion. That's a 63% annualized growth rate, which could yield substantial returns for investors.

Image source: Getty Images.

2. Alphabet (Google) Alphabet is benefiting from the growing demand for AI cloud services and advertising. The company's revenue continues to grow at double-digit rates, with analysts expecting revenue to increase by 14% in 2026, reaching $455 billion.

AI is a competitive advantage for the company. It has been investing in AI since 2015, and the results are paying off. AI is improving the effectiveness of ad spending on Search, YouTube, and other Google services, resulting in more personalized ads for 2 billion users.

Google Search saw its revenue surge 16% year over year in the third quarter. A catalyst for more growth is the recent launch of AI Max, which can deliver more relevant ads to users by matching advertisers with a larger pool of billions of search queries.

Today's Change

(

1.02

%) $

3.31

Current Price

$

328.75

Profitable advertising revenue is contributing to strong growth in operating cash flow. Google is generating over $151 billion in cash from operations, while investing massive amounts in AI infrastructure, including chips and data centers. Despite capital expenditures increasing 58% year over year on a trailing-12-month basis, the company's free cash flow is growing.

Alphabet stock returned 783% over the last 10 years, driven by a rise in free cash flow from $16 billion in 2015 to an expected $65 billion in 2025. Analysts expect Alphabet's free cash flow to grow to $157 billion by 2029. That's more than double its trailing free cash flow, which could also double the share price within the next five years.

The stock has been a huge winner over the past year.

Applied Digital (APLD +17.97%) shares soared higher after the company reported another strong quarter of revenue growth and revealed that it was in advanced talks with multiple hyperscalers (owners of large data centers) for 900 megawatts of data center capacity.

The stock is up about 250% over the past year, as of this writing. Let's dig into what Applied Digital does, and whether or not it's too late to buy the stock.

Today's Change

(

17.97

%) $

5.74

Current Price

$

37.68

Strong fiscal Q2 revenue growth Applied Digital has been a big artificial intelligence (AI) infrastructure winner, but it is actually more of a specialized real estate company than it is a tech company. In fact, it recently announced it was spinning out its cloud computing business and merging it with EKSO Bionics Holding (EKSO 3.17%) to form a new company called ChronoScale. This business would sometimes come into conflict with its customers, and the company is also looking to convert into a real estate investment trust (REIT).

Applied Digital builds and runs data centers that are tailored for handling AI workloads, like training large language models and inference. The company has been able to carve out a strong niche in the space through its access and ability to source cheap power, which it gained when it was a Bitcoin miner. In fact, it still operates a data center hosting business that caters to the crypto mining space. Today, access to power is one of the biggest bottlenecks in the AI infrastructure space, which has helped drive strong growth for the company.

Applied Digital's rapid revenue growth continued in its fiscal second quarter, with revenue surging 250% to $126.6 million. The company's high-performance computing (HPC) business contributed revenue of $85 million, with $73 million of that coming from tenant fit-out services, which is revenue it gets from building out specialized facilities for large customers. This is still largely work being done for CoreWeave. Tenant fit-out services have low gross margins, but they set the stage for higher-margin recurring revenue growth in the future.

Its data center hosting business, meanwhile, grew its revenue by 15% to $41.6 million, with operating income of $16 million. This business consists of two facilities in North Dakota that use 286 megawatts of power for cryptocurrency mining.

On the profitability front, the company reported adjusted net income of $0.1 million and flat adjusted earnings per share (EPS). Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $20.2 million, compared to $6.1 million a year ago.

It ended the quarter with $1.9 billion in cash against $2.6 billion in debt on its balance sheet. It had operating cash flow of negative $97.9 million and negative free cash flow of $899.4 million through the first half of its fiscal year.

Image source: Getty Images.

Is it too late to buy the stock? While Applied Digital turned in solid results, what got investors the most excited was its comments about being in advanced discussion with some large cloud computing providers for 900 megawatts of power across two to three sites.

The company's HPC business is currently only at 100 megawatts of power following the completion of its first building at its Polaris Forge 1 campus. That will ramp up to 400 megawatts for CoreWeave by the end of 2027. It also has a 200-megawatt commitment from another customer at its Polaris Forge 2 campus, with some initial capacity projected to come online this year, and a full build-out in 2027.

These projects should lead to a ton of growth moving forward, and the company has the financing in place to complete these projects. The key will be for it to show good returns and operating leverage on these buildouts. If it can do that, the stock has strong upside.

However, given the costs to build out these data centers and its current lack of cash flow, it does put the stock in the high-risk-reward bucket. Investors may want to take a more cautious approach given the stock's huge gains over the past year.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Primo Brands to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities: (a) the common stock of Primo Water between June 17, 2024 through November 8, 2024, inclusive, and/or (b) the common stock of Primo Brands between November 11, 2024 through November 6, 2025, inclusive (collectively, the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Primo Brands Corporation ("Primo Brands" or the "Company") (NYSE: PRMB) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the merger between Primo Water and BlueTriton Brands, including facts regarding the progress of the merger integration. Defendants issued a series of materially false and misleading statements that led investors to believe the merger would accelerate growth, generate transformative operational efficiencies, achieve meaningful synergies, and deliver strong financial results, and that the merger integration was proceeding "flawlessly."

Investors began to uncover problems at Primo Brands on August 7, 2025, when the company reported its Q2 2025 earnings and disclosed that its merger had caused disruptions in product supply, delivery, and service. Following this revelation, the company's stock price fell $2.41 or about 9%, dropping from $26.41 on August 6, 2025 to $24.00 on August 7, 2025.

The full extent of the issues became apparent on November 6, 2025, when Primo Brands sharply reduced its full-year 2025 net sales and adjusted EBITDA guidance and announced the replacement of CEO Rietbroek. During a conference call that day, new CEO Eric Foss acknowledged that the company had moved "too far too fast" with integration efforts, leading to warehouse closures, route realignment problems, customer service issues, and technology-related integration failures.

After this disclosure, the stock dropped $8.20 or 36% over the next two trading sessions, falling from $22.66 on November 5, 2025 to $14.46 on November 7, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Primo Brands' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Primo Brands class action, go to www.faruqilaw.com/PRMB or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279960

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing Strong cash position: preliminary unaudited cash, cash equivalents and marketable securities of approximately $373.7 million as of December 31, 2025, expected to fund operations into 2029 CARMEL, Ind., Jan. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced it will provide an update on its clinical programs, expanding obesity pipeline, and outlook for 2026 during the Company's presentation at the 44th Annual J.P.

Vanguard is recognized for managing some of the world's top real estate ETFs. But does one of its ETFs compare to the largest global real estate ETF?

Both the Vanguard Global ex-U.S. Real Estate ETF(VNQI +0.11%) and iShares Global REIT ETF (REET +0.00%) target global real estate equities, providing exposure to real estate investment trusts (REITs) worldwide. This comparison highlights their differences in cost, performance, risk, and portfolio composition, helping investors assess which may better fit their needs.

Snapshot (cost & size)MetricVNQIREETIssuerVanguardISharesExpense ratio0.12%0.14%1-yr return (as of Jan. 8, 2026)19.58%6.65%Dividend yield4.58%3.62%*Beta0.710.97AUM$3.53 billion$4.33 billion*Beta measures price volatility relative to the S&P 500; beta is calculated from five-year weekly returns.

Both ETFs are low-cost, though VNQI is slightly more affordable by 0.02 percentage points. VNQI offers a higher dividend yield, which may appeal to income-focused investors seeking a larger return from real estate equities.

Performance & risk comparisonMetricVNQIREETMax drawdown (5 y)-35.76%-32.09%Growth of $1,000 over 5 years$857$1,053What's insideEstablished in 2014, REET is the largest global real estate ETF by total assets and average volume, currently holding 377 assets worldwide (as of Jan. 8, 2026). Its largest positions are Welltower (WELL 0.12%), Prologis (PLD +0.79%), and Equinix (EQIX +2.36%), which together account for nearly 20% of its total assets.

VNQI, in contrast, does not include any U.S. real estate stocks and REITS in its holdings, and instead primarily focuses on developed international markets, especially in the Asia-Pacific and European regions. Its top holdings include Goodman Group (ASX:GMG.AX), Mitsui Fudosan Co., Ltd. (JPX:8801.T), and Mitsubishi Estate Co., Ltd. (JPX:8802.T). The ETF has 742 total holdings, with no single asset accounting for more than 4% of its weight, making its diversification more even than top-heavy.

What this means for investorsVNQI has a higher dividend yield, more total holdings, and had a very strong year in 2025. However, there are a few things investors should be aware of when comparing the fund to REET.

Outside of no U.S. assets in its holdings, the ETF has had a 5-year price change of -12.7%, compared to REET increasing 8.3% in that span. In addition,  VNQI pays out dividends annually, which is less frequent than REET's quarterly payments, and the annual dividend is more of a lump sum payment. The payout ratio of the iShares ETF also has a 96% dividend payout ratio, nearly 25% higher than Vanguard's, which shows that the REET fund is more committed to returning profits to investors.

For those who don't mind having less exposure to the U.S. real estate market and seek short-term gains, VNQI appears more ideal. But for exposure to all global real estate assets, more consistent payouts, and long-term gains, REET may be the better option.

GlossaryETF: Exchange-traded fund that holds a basket of assets and trades like a stock.
Expense ratio: Annual fund operating costs expressed as a percentage of the fund's average assets.
Dividend yield: Annual dividends paid by a fund divided by its current share price.
REIT: Real estate investment trust, a company owning or financing income-producing real estate.
Beta: Measure of an investment’s volatility compared with the overall stock market, often the S&P 500.
AUM: Assets under management; total market value of all assets a fund manages.
Max drawdown: Largest peak-to-trough decline in an investment’s value over a specified period.
Total return: Investment performance including price changes plus all dividends and distributions, assuming reinvestment.
Developed markets: Economically advanced countries with mature financial systems and stable regulatory environments.
Holdings: Individual securities or positions owned within an investment fund’s portfolio.

For more guidance on ETF investing, check out the full guide at this link.

San Diego, California--(Newsfile Corp. - January 11, 2026) - Robbins Geller Rudman & Dowd LLP announces that investors in SLM Corporation a/k/a Sallie Mae (NASDAQ: SLM) (NASDAQ: SLMBP) securities between July 25, 2025 and August 14, 2025, inclusive (the "Class Period"), have until February 17, 2026 to seek appointment as lead plaintiff of the SLM class action lawsuit. Captioned Zappia v. SLM Corporation a/k/a Sallie Mae, No. 25-cv-18834 (D.N.J.), the SLM class action lawsuit charges SLM as well as certain of SLM's top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the SLM class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-slm-corporation-a-k-a-sallie-mae-class-action-lawsuit-slm-slmbp.html

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: SLM, through its subsidiaries, originates and services private education loans ("PELs").

The SLM class action lawsuit alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) SLM was experiencing a significant increase in early stage delinquencies; and (ii) accordingly, defendants overstated the effectiveness of SLM's loss mitigation and/or loan modification programs, as well as the overall stability of SLM's PEL delinquency rates.

The SLM investor class action further alleges that on August 14, 2025, investment bank TD Cowen issued a report addressing SLM, flagging that, "[o]verall, July [2025] delinquencies were up 49 bp m/m, higher (worse) than the seasonal (+10 bps) performance for July, driven by a 45 bps increase in early stage delinquencies." Notably, TD Cowen's findings directly contradicted assurances made by SLM's CFO, defendant Peter M. Graham – made late in the month of July 2025 – that defendants were observing delinquency rates that "really are following the normal seasonal trends we would expect in the business," the complaint alleges. Following this news, the price of SLM's stock fell by approximately 8%, the SLM shareholder class action claims.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who invested in SLM securities during the Class Period to seek appointment as lead plaintiff in the SLM class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the SLM investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the SLM shareholder class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the SLM class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279888

Source: Robbins Geller Rudman & Dowd LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Specializing in spinal surgery devices, this medical technology firm reported a notable insider sale amid strong 12-month share price gains.

Miles Patrick, the CEO of Alphatec Holdings (ATEC 0.13%), executed an open-market sale of 100,000 shares on Monday for a total consideration of $2.1 million according to a recent SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)100,000Transaction value$2.1 millionPost-transaction shares (direct)5.14 millionPost-transaction value (direct ownership)$108.9 millionTransaction value based on SEC Form 4 weighted average purchase price ($21.01); post-transaction value based on Monday weighted average price ($21.01).

Key questionsHow significant was the transaction relative to Patrick’s historical trading pattern?
The 100,000-share sale matches the recent median open-market transaction size, indicating that this disposition was typical for the period since November 2024 and not unusually large or small for Patrick’s activity.What impact did this transaction have on direct and aggregate insider ownership?
The sale reduced Patrick’s direct holdings by 6.82%, leaving him with 5,135,398 directly held shares and maintaining substantial exposure, while indirect holdings via an IRA and an LLC entity remain unchanged at 260,900 shares.Did the transaction reflect a change in cadence or remaining saleable capacity?
The steady 100,000-share cadence over recent months reflects a normalization to available holdings, as Patrick’s holdings has declined by about 20% over the past year, constraining the size of further dispositions.How does the transaction valuation compare to recent price performance?
The shares were sold at around $21.01 per share, with the stock closing at $21.20 that day and up 126.3% over the prior 12 months, indicating the transaction captured proceeds near prevailing highs amid strong price momentum.Company overviewMetricValueRevenue (TTM)$728.02 millionNet income (TTM)($154.96 million)Price (as of Monday)$21.011-year price change126.3%Company snapshotAlphatec Holdings offers a comprehensive portfolio of spinal surgery devices, including neural monitoring systems, spinal fixation platforms, interbody implants, biologics, and patient positioning solutions.The company generates revenue primarily through the sale of proprietary medical devices and related products to hospitals and surgical centers, distributed via a direct sales force and independent distributors in the United States.It serves spine surgeons and healthcare providers specializing in the surgical treatment of spinal disorders, targeting both degenerative and complex pathologies.Alphatec Holdings is a U.S.-based medical device company focused on advancing surgical solutions for spinal disorders. Through continuous innovation in device design and procedural integration, the company aims to improve patient outcomes and surgical efficiency in the spine market.

With a broad product suite and a specialized sales network, Alphatec Holdings leverages its expertise to address the evolving needs of spine surgeons and healthcare facilities, positioning itself as a technology-driven leader in the medical devices sector.

What this transaction means for investorsFor long-term investors, insider selling only matters if it conflicts with fundamentals or signals a change in conviction. In this case, neither appears to be true. Alphatec Holdings continues to execute against a growth playbook that has materially outpaced the broader market, and this transaction fits squarely within that context.

Operational momentum remains strong. In its most recent quarter, Alphatec reported revenue of $197 million, up 30% year over year, with surgical revenue climbing 31% to $177 million. Meanwhile, adjusted EBITDA reached $26 million, expanding margins by more than 800 basis points. Management also raised full-year guidance, projecting roughly $760 million in revenue and about $91 million in adjusted EBITDA, up substantially from previous expectations of $83 million and underscoring confidence in sustained demand across its spine portfolio.

Also important to note: The sale itself was executed under a prearranged Rule 10b5-1 plan and represented a modest trim rather than a directional shift. Even after the transaction, the CEO retains more than 5.1 million directly held shares, alongside additional indirect exposure, keeping his economic alignment with shareholders firmly intact. Ultimately, planned liquidity events like this don’t alter the long-term thesis.

GlossaryOpen-market sale: The sale of securities on a public exchange, available to any buyer at market prices.
SEC Form 4: A regulatory filing disclosing insider trades of a company's securities by officers, directors, or significant shareholders.
Insider ownership: The percentage of a company's shares held by its executives, directors, or other insiders.
Direct holdings: Shares owned personally by an individual, not through trusts or other entities.
Indirect holdings: Shares owned through entities like trusts, IRAs, or LLCs, not held directly by the individual.
Disposition: The act of selling or otherwise transferring ownership of an asset or security.
Weighted average price: The average price of shares sold, weighted by the number of shares at each price.
Cadence: The frequency or regularity with which transactions or activities occur over time.
Proprietary medical devices: Medical products designed, developed, and owned exclusively by a specific company.
TTM: The 12-month period ending with the most recent quarterly report.
Spinal fixation platforms: Medical devices used to stabilize and support the spine during or after surgery.
Biologics: Products derived from living organisms used in medical treatments, such as to promote bone growth in surgery.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Dutch Bros shareholders have benefited from a rapid regional to national expansion.

Dutch Bros (BROS 1.13%) has gained increased investor attention in recent years. A unique concept and a rapid expansion across the U.S. stoked fast revenue growth and increased recognition, particularly at a time when its largest rival, Starbucks, is looking for ways to reinvigorate its brand.

Nonetheless, Dutch Bros is still a fraction of Starbucks' size, and consumers have numerous choices when it comes to coffee and beverages. Amid those conditions, can the coffee stock perk up investor returns, or should they look for caffeine highs elsewhere?

Image source: Getty Images.

The state of Dutch Bros Dutch Bros has stood out in the crowded coffee marketplace. It operates drive-thru coffeeshops, attempting to reach out to customers by adding a personal touch between customers and employees, who it calls "broistas." It also empowers shops to host local events for organizations with its focus on giving back to the communities its serves.

Additionally, it has developed a customer following with breve drinks, which are based on espresso and half-and-half. It also offers teas, smoothies, lemonades, energy drinks, and other beverages.

The company has also taken this concept across the country rapidly. As of the end of the third quarter of 2025, it operated 1,081 shops in 24 states, well above the 471 locations it had when it announced its IPO in 2021.

Financial growth Amid that growth, Dutch Bros reported about $1.2 billion in revenue in the first nine months of 2025, a 27% yearly increase. This included 5.2% same-shop sales growth over the same period, an indication of its rising popularity.

During that time, the company kept cost and expense growth in check. As a result, it earned $58 million in net income in the first three quarters of 2025, rising 85% from year-ago levels.

That growth helped the stock early in 2025, but over the last year, it is up by just 12%. Valuation may partially explain that slowdown, as Dutch Bros shares trade at a 126 P/E ratio, far above the S&P 500 average of 31.

Today's Change

(

-1.13

%) $

-0.71

Current Price

$

62.35

Nonetheless, Dutch Bros intends to grow to 2,029 shops by 2029. Such growth is bullish for Dutch Bros, but it remains to be seen whether investors are willing to overlook the high valuation to buy into this growth story.

Is Dutch Bros a long-term winner? Given its rapid growth, Dutch Bros stock should be a long-term winner.

Admittedly, the high valuation and competitive nature of Dutch Bros' business may give investors pause. Even though its rapid growth arguably commands a premium, it also makes the stock's near-term direction uncertain. Knowing that, investors should accumulate shares slowly if they choose to invest.

Still, the fact that the store footprint is set to almost double in three years should bode well for Dutch Bros stock and its financials. That means investors should expect the rapid revenue growth to continue for the foreseeable future, a factor that should take the stock higher over time.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Firefly Aerospace To Contact Him Directly To Discuss Their Options

If you purchased or otherwise acquired: (a) Firefly common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about August 7, 2025 (the "IPO" or "Offering"); and/or (b) Firefly securities between August 7, 2025 and September 29, 2025, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Firefly Aerospace Inc. ("Firefly" or the "Company") (NASDAQ: FLY) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Firefly had overstated the demand and growth prospects for its Spacecraft Solutions offerings; (2) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (3) the foregoing, once revealed, would likely have a material negative impact on the Company; and (4) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

Firefly conducted its August 7, 2025 IPO pursuant to the Offering Documents, selling 19.296 million shares of common stock priced at $45.00 per share.

On September 22, 2025, Firefly reported its financial results for the second quarter of 2025, its first earnings report as a public company. Among other items, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to $58.7 million, or $4.60 per share, for the same quarter in 2024. Firefly also reported revenue of $15.55 million, below analyst estimates of $17.25 million and down 26.2% from the same quarter in 2024. Significantly, Firefly reported revenue of only $9.2 million in its Spacecraft Solutions business segment, representing a 49% year-over-year decrease.

On this news, Firefly's stock price fell $7.58 per share, or 15.31%, to close at $41.94 per share on September 23, 2025.

Less than one week later, on September 29, 2025, Firefly disclosed that "the first stage of Firefly's Alpha Flight 7 rocket experienced an event that resulted in a loss of the stage." Notably, Firefly CEO Jason Kim stated during the September 22, 2025 earnings call that the Company "expect[ed] to launch Flight 7 in the coming weeks." Following on the heels of Firefly's failed April 2025 Alpha rocket launch, the Alpha 7 test failure raised significant questions about Firefly's ability to meet its commercial launch commitments and the viability of the Company's technology.

On this news, Firefly's stock price fell $7.66 per share, or 20.73%, to close at $29.30 per share on September 30, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Firefly's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Firefly Aerospace class action, go to www.faruqilaw.com/FLY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279956

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR.

Alphabet CEO Sundar Pichai speaks at a Google I/O event in Mountain View, Calif., Tuesday, May 20, 2025. Credit: AP Photo/Jeff Chiu, File Google said Sunday that it is expanding the shopping features in its AI chatbot by teaming up with Walmart, Shopify, Wayfair and other big retailers to turn the Gemini app into a virtual merchant as well as an assistant.

An instant checkout function will allow customers to make purchases from some businesses and through a range of payment providers without leaving the Gemini chat they used to find products, according to Walmart and Google.

The news was announced on the first day of the National Retail Federation's annual convention in New York. The role of artificial intelligence in e-commerce and its impact on consumer behavior are expected to dominate the three-day event.

"The transition from traditional web or app search to agent-led commerce represents the next great evolution in retail," John Furner, Walmart's incoming president and CEO, said in a joint statement with Google and Alphabet CEO Sundar Pichaei.

Google's new AI shopping feature works this way: if a customer asks what gear to get for a winter ski trip, for example, Gemini will return items from a participating retailers' inventory.

In the case of Walmart, customers who link their Walmart and Gemini accounts will receive recommendations based on their past purchases, and any products they decide to buy via the chatbot could get combined with their existing Walmart or Sam's Club online shopping carts, according to the statement.

OpenAI and Walmart announced a similar deal in October, saying the partnership would allow ChatGPT members to use an instant checkout feature to shop for nearly everything available on Walmart's website except for fresh food.

Google, OpenAI and Amazon all are racing to create tools that would allow for seamless AI-powered shopping by taking chatbot users from browsing to buying within the same program instead of having to go to a retailer's website to complete a purchase. The race between OpenAI and Google has heated up in recent months.

Before the recent holiday shopping season, OpenAI launched an instant checkout feature within ChatGPT that allows users to buy products from select retailers and Etsy sellers without leaving the app.

San Francisco software company Salesforce estimated that AI influenced $272 billion, or 20%, of all global retail sales, in one way or another during the holiday shopping season.

Google said the AI-assisted shopping features in Gemini only would be available to U.S. users initially but that it planned to expand internationally in the coming months.

© 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Google teams up with Walmart and other retailers to enable shopping within Gemini AI chatbot (2026, January 11) retrieved 11 January 2026 from https://techxplore.com/news/2026-01-google-teams-walmart-retailers-enable.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

This enterprise finance software provider saw a significant insider sale amid ongoing shifts in direct ownership, SEC filings reveal.

Jonathan Mariner, a director at OneStream (OS +0.09%), sold 7,956 shares in open-market transactions on Tuesday, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)7,956Transaction value$185,436.09Post-transaction shares (direct)7,130Post-transaction value (direct ownership)$168,339.30Transaction value based on SEC Form 4 weighted average purchase price ($23.31); post-transaction value based on Tuesday market close ($23.31).

Key questionsHow significant was this sale relative to Mariner's remaining stake?
This transaction accounted for 52.74% of Mariner's direct ownership, cutting his holding from 15,086 to 7,130 shares.Was this trade size typical compared to Mariner's prior activity?
The 7,956-share sale was above Mariner's recent median sell size of 6,630.5 shares, with the percentage of holdings traded notably higher than the recent median of 15.3% per sale, due to the reduced number of shares left to sell.Did this transaction involve any indirect holdings or derivative activity?
No; all shares were sold from Mariner's direct account, with no disposition from trusts or related entities and no involvement of options or restricted stock unit exercises.How does the sale align with Mariner's historical trading pattern and capacity?
Mariner's recent sales have escalated in proportion of holdings as his available shares diminished, and this transaction reflects a final stage of direct position reduction rather than a change in trading intent or cadence.Company overviewMetricValuePrice (as of Tuesday)$23.31Market capitalization$6 billionRevenue (TTM)$570.68 million1-year price change(10.47%)Company snapshotOneStream delivers a unified, AI-enabled Digital Finance Cloud platform offering financial close and consolidation, planning, analysis, and end-to-end financial and operational reporting solutions.The company serves large enterprises, mid-market organizations, and government entities seeking scalable, integrated financial management tools.OneStream is a technology company specializing in enterprise financial software, with a core focus on unified, extensible cloud-based solutions. The company leverages AI-driven automation to streamline complex financial processes for organizations with demanding reporting and planning requirements.

What this transaction means for investorsMariner’s sale looks procedural rather than thesis-changing. The transaction was executed under a pre-arranged Rule 10b5-1 plan, and while it reduced his direct holdings by more than half, proxy disclosures show he continues to hold a meaningful Class C stake. The elevated percentage sold reflects a shrinking pool of directly held shares, not a sudden loss of confidence.

Why this move matters for long-term investors is less about a single insider trimming exposure and more about how governance-driven selling intersects with a stock that has underperformed despite improving fundamentals. OneStream’s shares are down about 10% over the past year, lagging the S&P 500’s roughly 18% gain, even as the company continues to post solid subscription growth and narrowing losses.

Third-quarter revenue rose 19% year over year to $154.3 million, driven by a 27% jump in subscription revenue to $140.9 million. The company also delivered non-GAAP operating income of $9.3 million, up from $5.5 million a year earlier, and generated positive free cash flow of $4.8 million. That combination suggests improving operating leverage as OneStream scales its finance platform.

Ultimately, insider selling here does not contradict the company’s improving financial trajectory. The bigger question is whether OneStream can translate strong subscription growth and margin progress into sustained stock performance.

GlossaryInsider trading: The buying or selling of a company's stock by its executives, directors, or employees.
SEC Form 4: A required filing that discloses insider trades of company stock by officers, directors, or major shareholders.
Direct holdings: Shares owned personally by an individual, not through trusts, funds, or other entities.
Indirect holdings: Shares owned through trusts, family members, or related entities rather than directly by the individual.
Derivative transactions: Trades involving financial contracts whose value is based on an underlying asset, such as options or futures.
Restricted stock unit (RSU): A form of compensation giving employees rights to company shares after certain conditions are met.
Disposition: The act of selling or otherwise transferring ownership of an asset or security.
Weighted average purchase price: The average price paid per share, weighted by the number of shares bought at each price.
Outstanding shares: The total number of a company's shares currently held by all shareholders.
Median sell size: The middle value of all recent share sale sizes, used to measure typical transaction amounts.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

This AI-powered fintech firm reported notable insider selling following a year of strong share gains and ongoing platform expansion.

Tami Rosen, the chief development officer of Pagaya Technologies Ltd. (PGY +4.32%), executed an open-market sale of 7,561 shares on Dec. 19, according to a SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)7,561Transaction value$232,400Post-transaction shares (direct)37,544Transaction value based on SEC Form 4 weighted average purchase price ($30.73).

Key questionsHow significant was this trade relative to Rosen's prior selling activity?
After the transaction, Rosen reported holding 37,544 Class A ordinary shares directly.How did trade size compare to Rosen's historical pattern?
The 7,561-share sale was smaller than the median recent-period sale of 13,842 shares.Were options or indirect holdings involved in this transaction?
No; the sale was strictly direct open-market equity, with no activity in indirect accounts or via derivative exercises.What market context surrounded the sale?
The transaction occurred as shares were priced at around $30.73 per share, above the Dec. 19 market close of $22.85, following a one-year total return of 118.28% as of the transaction date.Company overviewMetricValueRevenue (TTM)$1.22 billionNet income (TTM)($190.83 million)1-year price change118.28%* 1-year price change calculated using Dec. 19, 2025 as the reference date.

Company snapshotPagaya Technologies develops and deploys proprietary artificial intelligence software for loan origination and asset management, generating revenue primarily from technology solutions provided to financial partners.The company operates a platform-based business model, monetizing through transaction fees and software licensing with financial institutions and fintech partners.It serves high-growth fintech companies, incumbent banks, auto finance providers, and brokers across Israel, the United States, and the Cayman Islands.Pagaya Technologies Ltd. leverages advanced AI and data-driven infrastructure to streamline loan origination and asset management for institutional clients. The company’s scalable platform enables partners to optimize credit decisioning and expand access to financial products. Pagaya’s competitive edge lies in its proprietary technology and broad network of financial partnerships, positioning it as a key enabler in the evolving fintech ecosystem.

What this transaction means for investorsPagaya’s shares have far outpaced the broader market over the past year, reflecting a sharp operational turnaround and growing confidence in the company’s AI-driven credit platform. However, it’s important to note here that the Dec. 19 sale was executed under a pre-established Rule 10b5-1 trading plan, removing discretion from the timing. The Form 4 also notes the transaction did not involve derivatives or indirect entities, underscoring a straightforward reduction of a modest position rather than a structural shift in ownership. After the sale, Rosen still retained a relatively meaningful equity stake.

Operationally, Pagaya’s most recent quarter supports the stock’s strong run. The company posted GAAP net income of $23 million, a $90 million year-over-year improvement, alongside record revenue of $350 million and adjusted EBITDA of $107 million, which climbed 91% year over year. Management also raised full-year guidance across revenue, profitability, and network volume, reinforcing that recent gains were driven by execution rather than multiple expansion alone.

Ultimately, insider sales tied to trading plans amid improving profitability and raised guidance do not, on their own, undermine the broader thesis. The more relevant signal remains whether Pagaya can sustain disciplined underwriting and operating leverage as it scales.

GlossaryOpen-market sale: The direct sale of securities on a public exchange, not through private transactions or pre-arranged deals.
Direct equity position: Shares owned personally by an individual, not through trusts, funds, or other entities.
SEC Form 4: A regulatory filing disclosing insider trades by company officers, directors, or major shareholders.
Weighted average price: The average price per share, adjusted for the number of shares sold at each price.
Systematic liquidation: The planned, gradual sale of holdings over a period, rather than all at once.
Derivative instruments: Financial contracts whose value is based on underlying assets, such as options or futures.
Indirect entities: Accounts or organizations through which an individual holds securities, rather than owning them directly.
Transaction value: The total dollar amount received from selling securities in a specific transaction.
Post-transaction value: The value of an individual's holdings after a trade or series of trades is completed.
One-year total return: The combined gain from price appreciation and dividends over the past year, expressed as a percentage.
Proprietary technology: Technology owned and controlled by a company, often protected by patents or trade secrets.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Pagaya Technologies. The Motley Fool has a disclosure policy.

Long-term investing can be a great path to wealth generation, but holding on to these stocks could cost you.

While the stock market has seen huge periods of volatility over the last 50 years, taking a buy-and-hold approach to funds tracking the S&P 500 and other leading indexes has proven to be one of the best ways to generate wealth. Those who invested in a basket of individual stocks and exchange-traded funds fared even better.

On the other hand, that doesn't mean that adopting long-term investment strategies will necessarily pan out for all stock buyers. Some stock picks are going to lose money. Read on for a look at three popular stocks that look like risky plays for long-term investors right now.

Image source: Getty Images.

1. Lucid Lucid (LCID +0.80%) is a specialist in the electric vehicle (EV) market and is making a name for itself as a provider of high-quality luxury vehicles in the category. Across its core Air sedan and Gravity SUV lines, the company's vehicles have generally received high marks from industry experts, media outlets, and vehicle owners.

The company also received a notable endorsement from Uber Technologies last year, with the ride-hailing leader signing a partnership to secure at least 20,000 vehicles from the EV manufacturer to support its robotaxi initiatives. On the other hand, the quality of Lucid's business appears to diverge substantially from the quality of its vehicles.

Today's Change

(

0.80

%) $

0.09

Current Price

$

11.33

As a specialized and relatively young player in the EV market, it's not surprising that Lucid has been posting big losses. The company's business model ostensibly takes pages out of Tesla's playbook and aims to forge a path to profitability by harnessing economies-of-scale benefits that come with a rapidly expanding manufacturing footprint. On the other hand, there are big reasons to doubt whether Lucid will be able to execute along those lines.

Luicd has continued to rack up massive losses, and it's also continued to dilute retail investors by selling large blocks of new shares to Saudi Arabia's Public Investment Fund (PIF). These dynamics look poised to continue for the foreseeable future.

2. Plug Power Plug Power (PLUG 5.60%) has positioned itself as a pioneer in hydrogen-fuel-cell and electrolyzer technologies. In last year's third quarter, the company touted sales of $65 million for its GenEco electrolyzer business -- up 46% on a sequential quarterly basis and 13% year over year. On the other hand, total revenue came in at $177 million, representing a modest improvement over the roughly $174 million in sales it recorded in the prior-year period.

Like Lucid, Plug Power relies on issuing new stock and convertible bonds to raise funds. Along those lines, there's a good chance that investors who buy stock today will face substantial dilution.

Meanwhile, Plug Power posted a net loss of approximately $361 million in the quarter, with the outsized loss driven by write-downs, inventory factors, and restructuring expenses. These individual costs won't be recurring, but it also wouldn't be surprising to see the company announce more write-downs with subsequent quarterly reports.

Today's Change

(

-5.60

%) $

-0.13

Current Price

$

2.19

While its operating loss narrowed 49% year over year to roughly $90 million thanks to cost-efficiency initiatives and other catalysts, the extent to which the business will be able to improve operating margins along these lines is limited. Despite posting sales growth in the third quarter, the company's backlog actually declined 11% on a sequential quarterly basis as previously slated electrolyzer deals were recorded as revenue. With sales potentially set to begin declining again, as evidenced by the substantial drawdown for its order backlog, Plug Power is a very risky play right now.

3. Boeing Of the three stocks outlined as potential portfolio wreckers in this article, Boeing (BA +3.05%) probably stands the best chance of delivering wins for investors. The company has faced big challenges in recent years, with high-profile crashes for its airliners and big write-downs making headlines. On the other hand, there are some signs that the company's turnaround efforts could bear fruit. Boeing has sold off some non-core businesses, made acquisitions that could help support sustained growth, and shown encouraging order backlog momentum.

Today's Change

(

3.05

%) $

6.94

Current Price

$

234.32

Boeing posted sales of $23.3 billion in Q3 -- good for growth of roughly 28% year over year. On the other hand, the business still posted an operating loss of $5.05 billion in the period. The performance represented an improvement over the operating loss of $6 billion posted in the prior-year quarter, but that result is far from encouraging, given that the business also posted a big sales jump in the period.

With the company closing out Q3 with consolidated debt of roughly $53.4 billion, Boeing's financial dynamics continue to look fraught. With $6 billion in net losses over last year's first three quarters, the business's turnaround still has a long way to go. Investing in the stock at this stage may not offer enough upside potential given the headwinds at hand.

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.

Select Preliminary Unaudited 2025 Results

 Revenue  Three Months Ended
December 31, 2025 Twelve Months Ended
December 31, 2025Total Revenue$16M to $17M $66M to $67MYear-Over-Year Growth17% to 24% 19% to 20%  Other  Twelve Months Ended
December 31, 2025AVISE CTD Volume136,000 to 137,000AVISE CTD Trailing 12-month (TTM) average selling price$441 to $445Year-end cash and cash equivalents$32M   The select preliminary unaudited financial results reported today represent:

Record full year 2025 revenue, an increase of at least 19% over 2024AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024AVISE CTD test volume growth of at least 13,000, an 11% increase over 2024Year-end cash and cash equivalents of $32 million, a $10 million increase over 2024 “I am pleased to report the completion of another strong year for Exagen in which we’ve continued to make substantial progress in building a great company; a testament to continued execution across our commercial, scientific, and operational teams,” said John Aballi, President and CEO. “Based upon our preliminary results, we delivered significant topline growth, driven by both volume and ASP expansion, despite unexpected ASP headwinds in the second half of the year. We also strengthened our scientific and commercial teams and subsequently launched our first enhancements to the AVISE platform in several years, with more on the horizon. Our strong cash position and disciplined approach provide the flexibility to continue to invest in innovation and advance our strategy to change the standard of care in autoimmune disease while pursuing our goal of operating a profitable company.”

Cautionary Note Regarding Select Preliminary Unaudited Financial Results

Exagen is providing the above select preliminary unaudited financial information and results of operations as of and for the three months and year ended December 31, 2025, based on currently available information. The company’s financial closing procedures with respect to the estimated financial data provided above are not yet complete. These procedures often result in changes to accounts. The company’s independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to the select preliminary unaudited financial information and, accordingly, our independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto. As a result, the company’s final results may vary from the preliminary results presented above. Management undertakes no obligation to update or supplement the information provided above until it releases its audited financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP) for the year ended December 31, 2025.

About Exagen

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies and ambitions; the potential utility and effectiveness of Exagen’s services and testing solutions, additional enhancements to the AVISE platform; potential shareholder value and growth and profitability; preliminary financial information for 2025. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 4, 2025 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Jeff Black, Chief Financial Officer
Exagen Inc.
[email protected]

Tether Freezes Over $180 Million as Stablecoins Dominate Illicit Crypto FlowsStablecoin issuer Tether froze more than $182 million in USDT in a single day, targeting five Tron-based wallets during the last 24 hours.The move underscores how the stablecoins that dominate crypto trading remain highly centralized, with issuers able to block funds instantlyDespite frequent freezes tied to illicit activity, USDT’s market share and influence across the crypto economy remain largely intact.Tether, the issuer of the world’s largest stablecoin, froze more than $180 million worth of USDT over the last 24 hours.

On January 11, the blockchain tracking service Whale Alert flagged a series of five distinct freezing actions executed by Tether.

Why Did Tether Freeze Millions in USDT Without Warning?The operations targeted Tron-based wallets holding sums ranging from $12 million to $50 million, effectively wiping $182 million in value off the active ledger in a single day.

Sponsored

Sponsored

Tether’s USDT Stablecoin Freeze. Source: Whale AlertWhile the specific triggers for the seizures remain undisclosed, the scale and speed of the intervention point to high-level coordination with law enforcement agencies or a response to a critical security exploit.

The move highlights a paradox at the heart of the digital asset economy: while cryptocurrencies were designed to be censorship-resistant, the stablecoins that power 60% of the market are highly centralized.

Tether maintains the “admin keys” required to instantly freeze funds at the smart contract level. It frequently exercises this authority to comply with requests from the US Department of Justice, the FBI, and the Secret Service.

This aggressive compliance posture has become necessary as criminal networks increasingly pivot toward dollar-pegged tokens.

According to Chainalysis data, illicit finance activities have shifted dramatically. While Bitcoin was once the currency of choice for darknet markets, stablecoins represented 84% of all illicit transaction volume by the end of 2025.

Forensic data from AMLBot reinforces this trend. In a report released last December, the firm noted that Tether froze approximately $3.3 billion in assets between 2023 and 2025.

These enforcement actions were concentrated across the Ethereum (ERC-20) and Tron (TRC-20) networks, where Tether’s liquidity is deepest. During that same period, the issuer blacklisted 7,268 unique wallet addresses.

Despite the friction of these freezes, Tether’s market dominance remains unchallenged.

The token (USDT) currently has a market capitalization of nearly $187 billion, accounting for roughly 60% of the $308 billion stablecoin sector, according to DeFiLlama data.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

According to Bitrace, the cryptocurrency mixer Tornado Cash processed roughly $2.5 billion worth of Ethereum tokens in 2025. This is despite the privacy platform being under regulatory sanctions until March 2025.

Before and after the sanctions, however, activity has been non-stop on the fund mixing service.

Tornado Cash faced serious sanctions in 2022 from many Western countries, led by the United States, which placed sanctions on the privacy mixing platform that enables users to obscure transactions and make detection more difficult.

How did regulators react to Tornado Cash? The U.S. Treasury’s Office of Foreign Assets Control alleged that Tornado Cash facilitated money laundering of over $7 billion, including $455 million stolen by North Korea’s Lazarus Group, and has since prosecuted the founders, who to date are still fighting legal battles.

One of the founders, Alexey Pertsev, has already been sentenced to 64 months in prison. Cryptopolitan has reported that Roman Storm, another co-founder, is waiting to be sentenced, and the third co-founder is currently at large.

The sanctions placed on the platform resulted in a reduction in activity, but operations continued due to Tornado Cash’s decentralized architecture. The protocol has since then gained more notoriety as the go-to platform for people who want to obscure transactions for legitimate privacy reasons or bad actors who want to launder funds.

What’s the technology behind the privacy revolution? The technological foundation enabling these privacy protocols lies in zero-knowledge proofs (ZKP), a cryptographic technique that allows verification of information without revealing the data behind it.

It was first proposed by some MIT researchers in 1985, and since then, ZKP technology has moved from just a theoretical concept to a practical infrastructure supporting billions in transactions.

In Tornado Cash’s operating mechanism, users deposit cryptocurrency into smart contracts that pool funds from multiple sources. When withdrawing to a different address, users provide zero-knowledge proofs that show their ownership without revealing which deposit originated the withdrawal.

This makes it very difficult for external observers to trace fund movements, effectively breaking the transparent audit trail that is usually a feature in most blockchain transactions.

The privacy protocol ecosystem has also grown beyond Tornado Cash. Railgun, frequently mentioned by Ethereum founder Vitalik Buterin, saw net inflows of $1.4 billion in 2025, according to Bitrace.

Institutional players made considerable investments in privacy solutions in 2025, with Zcash receiving a lion’s share of those investments. The cryptocurrency, which is built with the same code as Bitcoin but with an added layer of privacy, caught the attention of users who wanted more privacy in their transactions.

The Zcash token has since increased by over 750% year-to-date, with a market capitalization of over $6.45 billion.

Another privacy platform, Monero, also saw considerable investments and now has a market capitalization of over $9.1 billion. However, these platforms are not crypto mixers like Tornado Cash, which may also contribute to their appeal.

The compliance challenge for Web3 entities The sanctions on Tornado Cash were lifted following a federal appeals court ruling that immutable smart contracts do not qualify as property under US law, establishing that regulators lacked authority to sanction the software itself.

However, this has not brought an end to the ongoing litigation and conversations regarding the protocol.

The fundamental question facing the industry is whether privacy can be reconciled with regulatory requirements. The current trajectory points to growing adoption of zero-knowledge proof technology across legitimate use cases, from confidential business transactions to privacy-preserving identity verification.

However, there is also increased usage by bad actors, and that is what regulators and other industry stakeholders must find a way to address without throwing the baby out with the bathwater—in other words, solve without taking steps that affect legitimate users.

Don’t just read crypto news. Understand it. Subscribe to our newsletter. It's free.

$XRP price is currently showing signs of a classic "calm before the storm." After a volatile start to 2026, the token is hovering around a critical support zone, waiting for a catalyst from the broader market—specifically Bitcoin (BTC)—to ignite its next move higher.

XRP Price Consolidates Near Strong SupportAs of January 11, 2026, XRP price is trading around the $2.08 level. Looking at the hourly charts, we can see a clear period of sideways movement following a sharp rejection from the $2.40 resistance area earlier this month.

XRP/USD 1H - TradingView

The current price action is remarkably stable, with the $2.06 - $2.10 range acting as a temporary floor. This zone aligns with previous accumulation phases, suggesting that bulls are actively defending this territory. The Stoch RSI on the 1-hour timeframe is currently in the oversold region, indicating that the selling pressure is exhausting and a local bounce is overdue.

The Bitcoin Correlation: A 20% Upside TargetHistory shows that XRP often lags behind $Bitcoin during the initial phase of a rally, only to outperform it once volatility peaks. Currently, Bitcoin is testing psychological support at $90,000. If BTC manages to reclaim the $93,000 level and move toward $100,000, XRP is positioned for a rapid catch-up play.

Why a 20% move is "easy" for XRP right now:

Gap to Resistance: The next major horizontal resistance sits at $2.35 - $2.40. A move from $2.08 to $2.35 represents a roughly 13% gain, while a full retest of the yearly high near $2.50 would constitute a 20% surge.Support Strength: The $2.00 psychological level is backed by the 50-day EMA, making it a "line in the sand" for traders.Low Volatility: The current low-volatility environment often precedes an impulsive breakout.XRP Price Prediction: Key Levels to WatchFor XRP to confirm a bullish reversal, it needs to break and hold above the $2.20 mark. This level has acted as a pivot point throughout the first week of January.

LevelTypeSignificance$2.45Major ResistanceRejection point; breakout here leads to $3.00.$2.20Immediate ResistanceLocal trend confirmation level.$2.08Current PriceConsolidation pivot.$2.00Psychological SupportStrongest floor in the current structure.If you are looking to secure your assets during these volatile periods, consider moving your long-term holdings to hardware wallets to ensure maximum security.